Skip to main
  1. Stocks
  2. Harmony Biosciences Holdings
  3. Forecast
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Harmony Biosciences Hldgs is supported by a resilient WAKIX franchise, with 3Q26 revenue of $268.9 million, about 400 net patient additions, and roughly 8,950 to 9,350 patients on therapy, while management reaffirmed 2026 net revenue guidance of $1.00 billion–$1.04 billion. The positive outlook is also driven by a well-funded balance sheet of about $1.05 billion in cash and investments, giving it flexibility to advance BP-205 and other CNS assets while pursuing larger business-development opportunities. Despite litigation and orexin competition, BP-205’s 94-patient MAD data, with no serious or severe adverse events and a roughly 29-hour half-life, plus pitolisant lifecycle catalysts such as GR and HD, strengthen the long-term growth case.

Bears say

Harmony Biosciences Hldgs is facing a negative fundamental setup because WAKIX remains exposed to intensifying competition in the sodium oxybate market, while earlier-than-expected generic pitolisant competition could directly pressure the company’s core revenue base. Growth in new patient adds for WAKIX may also slow more than expected, limiting momentum in its only commercial engine and leaving results highly dependent on one product. In addition, the pipeline carries meaningful binary risk, as clinical trials for PWS, DM1, DS/LGS, and Fragile X syndrome may fail to deliver, reducing the chance of near-term diversification.

HRMY has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

HRMY Analyst Forecast & Price Prediction

Get the latest HRMY stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HRMY

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 8 analysts, HRMY has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


HRMY Analyst Forecast & Price Prediction

Get the latest HRMY stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HRMY

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HRMY stock data and trends